News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,118 Results
Type
Article (35466)
Company Profile (723)
Press Release (659920)
Multimedia
Podcasts (131)
Webinars (21)
Section
Business (203931)
Career Advice (2209)
Deals (37354)
Drug Delivery (131)
Drug Development (81083)
Employer Resources (168)
FDA (16021)
Job Trends (15128)
News (345334)
Policy (30445)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1359)
Academic (1)
Accelerated approval (34)
Adcomms (22)
Allergies (151)
Alliances (49109)
ALS (180)
Alzheimer's disease (1628)
Antibody-drug conjugate (ADC) (341)
Approvals (16267)
Artificial intelligence (561)
Autoimmune disease (177)
Automation (40)
Bankruptcy (381)
Best Places to Work (11063)
BIOSECURE Act (23)
Biosimilars (195)
Biotechnology (445)
Bladder cancer (148)
Brain cancer (59)
Breast cancer (597)
Cancer (4716)
Cardiovascular disease (410)
Career advice (1846)
Career pathing (39)
CAR-T (286)
CDC (27)
Celiac Disease (1)
Cell therapy (779)
Cervical cancer (32)
Clinical research (69883)
Collaboration (1821)
Company closure (4)
Compensation (1198)
Complete response letters (75)
COVID-19 (2343)
CRISPR (98)
C-suite (936)
Cystic fibrosis (146)
Data (6254)
Decentralized trials (2)
Denatured (23)
Depression (146)
Diabetes (481)
Diagnostics (6708)
Digital health (47)
Diversity (6)
Diversity, equity & inclusion (39)
Drug discovery (266)
Drug pricing (202)
Drug shortages (30)
Duchenne muscular dystrophy (239)
Earnings (89575)
Editorial (59)
Employer branding (24)
Employer resources (148)
Events (118350)
Executive appointments (1035)
FDA (19165)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1495)
Gene editing (214)
Generative AI (49)
Gene therapy (631)
GLP-1 (1028)
Government (3285)
Grass and pollen (8)
Guidances (378)
Healthcare (16160)
HIV (63)
Huntington's disease (51)
IgA nephropathy (86)
Immunology and inflammation (279)
Immuno-oncology (70)
Indications (123)
Infectious disease (2623)
Inflammatory bowel disease (200)
Inflation Reduction Act (14)
Influenza (121)
Intellectual property (263)
Interviews (439)
IPO (17499)
IRA (54)
Job creations (4426)
Job search strategy (1514)
JPM (66)
Kidney cancer (16)
Labor market (85)
Layoffs (634)
Leadership (36)
Legal (7736)
Liver cancer (91)
Longevity (16)
Lung cancer (631)
Lymphoma (356)
Machine learning (42)
Management (60)
Manufacturing (864)
MASH (173)
Medical device (14009)
Medtech (14071)
Mergers & acquisitions (20950)
Metabolic disorders (1307)
mRNA (172)
Multiple sclerosis (168)
NASH (21)
Neurodegenerative disease (346)
Neuropsychiatric disorders (102)
Neuroscience (2943)
Neurotech (1)
NextGen: Class of 2026 (6058)
Non-profit (2057)
Now hiring (70)
Obesity (634)
Opinion (307)
Ovarian cancer (152)
Pain (215)
Pancreatic cancer (236)
Parkinson's disease (295)
Partnered (33)
Patents (529)
Patient recruitment (529)
Peanut (61)
People (59725)
Pharmaceutical (135)
Pharmacy benefit managers (30)
Phase 1 (21889)
Phase 2 (31071)
Phase 3 (23073)
Pipeline (5712)
Policy (289)
Postmarket research (2140)
Preclinical (8954)
Press Release (64)
Prostate cancer (245)
Psychedelics (56)
Radiopharmaceuticals (306)
Rare diseases (915)
Real estate (6077)
Recruiting (70)
Regulatory (23880)
Reports (42)
Research institute (1441)
Resumes & cover letters (346)
Rett syndrome (29)
RNA editing (16)
RSV (79)
Schizophrenia (157)
Series A (267)
Series B (205)
Service/supplier (26)
Sickle cell disease (104)
Special edition (26)
Spinal muscular atrophy (158)
Sponsored (30)
Startups (3981)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (100)
The Weekly (106)
Vaccines (971)
Venture capital (98)
Weight loss (425)
Women's health (81)
Worklife (23)
Date
Today (239)
Last 7 days (917)
Last 30 days (2877)
Last 365 days (30591)
2026 (4856)
2025 (30771)
2024 (35957)
2023 (40681)
2022 (51210)
2021 (54624)
2020 (51619)
2019 (42552)
2018 (32492)
2017 (33103)
2016 (31455)
2015 (36935)
2014 (30162)
2013 (25293)
2012 (26877)
2011 (27035)
2010 (25026)
Location
Africa (711)
Alabama (93)
Alaska (6)
Arizona (247)
Arkansas (12)
Asia (44436)
Australia (7109)
California (11745)
Canada (3332)
China (1187)
Colorado (486)
Connecticut (500)
Delaware (322)
Europe (94070)
Florida (1691)
Georgia (359)
Hawaii (4)
Idaho (59)
Illinois (807)
India (76)
Indiana (554)
Iowa (23)
Japan (449)
Kansas (124)
Kentucky (41)
Louisiana (25)
Maine (77)
Maryland (1287)
Massachusetts (8650)
Michigan (342)
Minnesota (644)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (26)
Nevada (125)
New Hampshire (84)
New Jersey (3121)
New Mexico (31)
New York (3004)
North Carolina (1595)
North Dakota (8)
Northern California (5752)
Ohio (322)
Oklahoma (18)
Oregon (48)
Pennsylvania (2301)
Puerto Rico (25)
Rhode Island (50)
South America (1110)
South Carolina (67)
South Dakota (1)
Southern California (4504)
Tennessee (148)
Texas (1754)
United States (41197)
Utah (338)
Vermont (1)
Virginia (266)
Washington D.C. (78)
Washington State (950)
West Virginia (4)
Wisconsin (118)
Wyoming (2)
696,118 Results for "ono pharmaceutical company ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical
January 7, 2026
·
2 min read
Press Releases
Ono to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
·
1 min read
Press Releases
Ono Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference Presentation
January 16, 2026
·
1 min read
Press Releases
Faron Pharmaceuticals Ltd: Holding(s) in Company
December 5, 2025
·
3 min read
Cancer
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera Pharmaceuticals in April 2024.
February 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Ono Announces ONO-4578 (EP4 antagonist) in Combination with Opdivo and Chemotherapy Met the Primary Endpoint in a Phase 2 Clinical Trial in Patients with Certain Gastric Cancer
October 10, 2025
·
3 min read
Deals
Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, “Ono”) today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc.
June 11, 2024
·
5 min read
Press Releases
Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy
October 10, 2025
·
3 min read
Deals
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.
April 29, 2024
·
10 min read
Deals
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
ONO Pharmaceutical, Co., Ltd., and Deciphera Pharmaceuticals, Inc. announced that on April 29, 2024, ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO.
April 30, 2024
·
10 min read
1 of 69,612
Next
